SmartPhone-Based Fitness and mHealth Device Users to Approach 100 Million by 2018
The next 5 years will see a major shift towards smartphone-based mHealth, where hardware attachments link to companion app on the smartphone, a new report from Juniper Research has found.
The report, "Mobile Health & Fitness: Monitoring, App-Enabled Devices & Cost Savings 2013–2018" forecasts that by 2018 there will be 96 million users of app-enabled mHealth and mobile-fitness hardware devices, up from 15 million this year. In the healthcare sector, App-enabled mHealth will be used to enable services ranging from remote patient monitoring to mobile ultrasound services.
mFitness to Set Pace
The report, however, found that it will be the mFitness sector that will experience strongest growth in the short and medium term. According to the report, this growth will be driven by a motivated target market, an increasing demand for lifestyle consumer applications and a diversifying array of attachments. App-enabled mFitness will therefore reach maturity much more quickly than smartphone-based mHealth, though it ultimately represents a much smaller market in terms of both users and revenues.
Importantly, it will also serve to educate the wider market as to what is possible through smartphone attachments: “As mobile fitness devices become more widespread, they will pave the way for more critical mHealth services delivered through the smartphone,” says the report’s author Anthony Cox. “While mHealth and mobile fitness are two discrete markets — with divergent audiences — increased usage of the former will stimulate wider awareness of the latter”
Further findings from the report include
• Juniper Research forecasts cumulative cost savings from remote patient monitoring of up to 35 billion USD during the next 5 years as the healthcare industry moves towards accountable care.
• Well-documented trials illustrating both health and cost-benefits crucial to convince stakeholders of the value of mHealth.
• Ageing populations and the increased prevalence of chronic disease is forcing healthcare stakeholders to reconsider how healthcare is addressed in both developing and developed markets.
The whitepaper, "Mobilising Healthcare", and further details of the full study "Mobile Health & Fitness: Monitoring, App-enabled Devices & Cost Savings 2013–2018" can be downloaded from www.juniperresearch.com
Juniper Research provides research and analytical services to the global hi-tech communications sector, providing consultancy, analyst reports and industry commentary.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance